WA-KYMETA
23.3.2022 14:02:14 CET | Business Wire | Press release
Kymeta (www.kymetacorp.com ), the communications company making mobile global, and IP Access International (www.ipinternational.net ), a leading mobile and fixed satellite solutions provider, announced today the signing of a partnership agreement to co-develop and distribute optimized solutions using Kymeta terminals, broadband and LTE services to first responders across North America.
Today, IP Access operates the nation’s largest public safety satellite network, which includes over 1,000 agency customers encompassing 1,700 unique endpoints. This agreement to deliver optimized solutions will combine Kymeta’s resilient and cost-effective electronically-steered flat panel technology with IP Access’ experience building public safety networks for mobility and remote connectivity where it has not previously existed. It will utilize coverage and bandwidth on a jointly developed, multi layered broadband network optimized specifically for public safety customers. The Kymeta enabled solution allows communication and interoperability among devices, further extending the reach of the IP Access RedPHONE service even if there is an internet outage due to malware or denial-of-service attacks.
“Kymeta is dedicated to bringing access to always-on, reliable, and mission-critical communications while on the move to the public safety and first responder market,” said Bill Marks, EVP and Chief Development Officer of Kymeta. “Our u8 products have been deployed around the world and provide a real-world solution for the defense, government, public safety, and commercial industries by enabling connectivity that is ubiquitous and more robust than ever before. We are pleased to partner with a well-established leader like IP Access who has earned the continued trust and loyalty of first responders for over two decades through the delivery of consistent, reliable products and services.”
“IP Access looks forward to a strong partner relationship with Kymeta in our joint efforts to provide resilient communications to response teams who protect and save lives,” said Bryan Hill, CEO of IP Access International. “Our customers are indifferent to what network they are on so long as it is reliable. Our goal at IP Access is to provide them with the connectivity they need on every possible network. That means 4G, 5G, GEO, MEO and LEO. Customers have capital constraints, and it is our responsibility to deliver solutions that are future proof and that is why we are partnering with Kymeta.”
The Kymeta u8 product family for mobile broadband communications are low-maintenance and low-profile for resilient communications-on-the-move (COTM) and communications-on-the-pause (COTP). The u8 product family also offers a pathway to low Earth orbit (LEO) networks as they come online over the next several years. The new partnership will allow IP Access to provide solutions that perform on today’s satellites and are enabled to work on future LEO satellite networks.
The partnership illustrates the commitment from both companies to enable critical mobile connectivity solutions for public safety and for disaster response that are more robust than ever before. Kymeta and IP Access have committed to a significant volume of equipment and satellite bandwidth to quickly fulfill the needs of public safety and first responders and grow the product suite and coverage in support of this important market.
About Kymeta
Kymeta is the leader in unlocking the potential of broadband satellite connectivity, combined with cellular networks, to satisfy the overwhelming demand for communications-on-the-move and making mobile global. Kymeta satellite connectivity solutions offer unique, complete, and turnkey bundled solutions to the market based on best-in-class technologies and tailored customer-centric services that meet and exceed customer mission requirements. These solutions, in tandem with the company’s flat-panel satellite antenna, the first of its kind, and Kymeta services provide revolutionary mobile connectivity on satellite and hybrid satellite-cellular networks to customers around the world. Backed by U.S. and international patents and licenses, the Kymeta terminal addresses the need for low-power, low-cost, and high-throughput communication systems that have no moving parts. Kymeta makes connecting easy – for any vehicle, vessel, aircraft, or fixed platform.
Kymeta is a privately held company based in Redmond, Washington.
For more information, visit kymetacorp.com
About IP Access International
IP Access is a leading provider of mobile and fixed satellite internet solutions with over 20 years experience serving the satellite industry as a domestic and global provider. IP Access provides complete satellite communications solutions inclusive of satellite network offerings, terminal hardware, and installation and support services. Incorporated in 1999, today IP Access operates the nation’s largest satellite network of public safety agencies, which includes over 1000 agency customers encompassing 1,700 unique endpoints. At the heart of the IP Access offering is the SELECT Network, providing multiple satellite options and multiple teleports, ensuring protection against regional disasters and infrastructure disruptions while also allowing for on-demand user selectable satellite service in the event of line-of-sight or look angle obstructions.
For more information, visit ipinternational.net
View source version on businesswire.com: https://www.businesswire.com/news/home/20220323005277/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom